Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept Posted on March 3, 2025March 3, 2025 by KBD Admin
Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors Posted on January 30, 2025February 3, 2025 by KBD Admin
Bluejay Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Brelovitug (BJT-778) for the Treatment of Chronic Hepatitis Delta Posted on January 21, 2025January 23, 2025 by KBD Admin
Maze Therapeutics Announces Oversubscribed $115 Million Financing to Support Advancement of Clinical-Stage Programs and Future Pipeline Posted on December 3, 2024December 4, 2024 by KBD Admin
Gilead and Tubulis Enter into Exclusive Option and Licence Agreement to Develop ADC Candidate for Select Solid Tumor Target Posted on December 3, 2024December 4, 2024 by KBD Admin
Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550 Posted on December 2, 2024December 4, 2024 by KBD Admin
35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity Posted on November 26, 2024November 27, 2024 by Frazier Web Host
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement Posted on October 31, 2024November 5, 2024 by KBD Admin
MBX Biosciences Announces Pricing of Initial Public Offering Posted on September 13, 2024September 26, 2024 by KBD Admin
Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline Posted on July 16, 2024September 26, 2024 by KBD Admin
